Related Experiment Video
Updated: Jan 30, 2026

Development of a Negative Selectable Marker for Entamoeba histolytica
Published on: December 12, 2010
Entamoeba Histolytica: Updates in Clinical Manifestation, Pathogenesis, and Vaccine Development
Micaella Kantor1, Anarella Abrantes1, Andrea Estevez1
1Kendall Regional Medical Center, Miami, FL, USA.
Abstract:
Entamoeba histolytica is the responsible parasite of amoebiasis and remains one of the top three parasitic causes of mortality worldwide. With increased travel and emigration to developed countries, infection is becoming more common in nonendemic areas. Although the majority of individuals infected with E. histolytica remain asymptomatic, some present with amoebic colitis and disseminated disease. As more is learned about its pathogenesis and the host's immune response, the potential for developing a vaccine holds promise. This narrative review outlines the current knowledge regarding E. histolytica and E. dispar and insight in the development of a vaccine.
Related Concept Videos
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Acute Pancreatitis II: Clinical Manifestations and Management
Angina III: Clinical Manifestations and Assessment
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Chronic Kidney Disease II: Clinical Manifestations

